Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

被引：20

作者：

Delabaudiere, Cyrielle ^{[1
]}

Lavayssiere, Laurence ^{[1
]}

Doerr, Gaelle ^{[1
]}

Muscari, Fabrice ^{[2
,3
]}

Danjoux, Marie ^{[4
]}

Sallusto, Federico ^{[5
]}

Peron, Jean Marie ^{[3
,6
]}

Bureau, Christophe ^{[3
,6
]}

Rostaing, Lionel ^{[1
,3
,7
]}

Izopet, Jacques ^{[3
,7
,8
]}

Kamar, Nassim ^{[1
,3
,7
]}

机构：

[1] CHU Rangueil, Dept Nephrol & Organ Transplantat, F-31059 Toulouse 9, France

[2] Univ Hosp Rangueil, Dept Surg & Liver Transplantat, Toulouse, France

[3] Univ Toulouse 3, F-31062 Toulouse, France

[4] CHU Purpan, Dept Pathol, Toulouse, France

[5] CHU Rangueil, Dept Urol & Kidney Transplantat, F-31059 Toulouse 9, France

[6] CHU Purpan, Dept Hepatol, Federat Digest, Toulouse, France

[7] CHU Purpan, IFR BMT, INSERM, U1043, Toulouse, France

[8] CHU Purpan, Virol Lab, Toulouse, France

来源：

TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 02期

关键词：

fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir; RECIPIENTS; THERAPY; PEGINTERFERON; INFECTION; ALPHA;

D O I：

10.1111/tri.12428

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.

引用

页码：255 / 258

页数：4

共 50 条

[21] Combination Therapy of Sofosbuvir and Simeprevir for Fibrosing Cholestatic Hepatitis C after Liver Transplantation.
Lang, Melanie
Polywka, Susanne
Kluwe, Johannes
Fischer, Lutz
Jordan, Sabine
Luetgehetmann, Mark
Nashan, Bjoern
Lohse, Ansgar
Sterneck, Martina
LIVER TRANSPLANTATION, 2014, 20 : S245 - S245
[22] Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin
Tang, S
Cheng, IKP
Leung, VKS
Kuok, UI
Tang, AWC
Ho, YW
Lai, KN
Chan, TM
JOURNAL OF HEPATOLOGY, 2003, 39 (05) : 875 - 878
[23] Response of fibrosing cholestatic recurrent hepatitis C following liver transplantation to combination interferon/ribavirin therapy
Lilly, Les
Deschenes, Marc
Marotta, Paul J.
HEPATOLOGY, 2007, 46 (04) : 479A - 480A
[24] An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
Nikroo Hashemi
Victor Araya
Kashif Tufail
Laxmi Thummalakunta
Eyob Feyssa
Ashaur Azhar
Mumtaz Niazi
Jorge Ortiz
World Journal of Hepatology, 2011, 3 (07) : 198 - 204
[25] Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin.
Samuel, D
HEPATOLOGY, 2003, 38 (04) : 531A - 531A
[26] An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
Hashemi, Nikroo
Araya, Victor
Tufail, Kashif
Thummalakunta, Laxmi
Feyssa, Eyob
Azhar, Ashaur
Niazi, Mumtaz
Ortiz, Jorge
WORLD JOURNAL OF HEPATOLOGY, 2011, 3 (07) : 198 - 204
[27] Treatment of Chronic Hepatitis with Sofosbuvir in Combination with Ribavirin with or without Pegylated Interferon
Sidhu, Sandeep S.
Malhi, Nirmaljeet
Singh, Rupinder
Gover, Rajiv
Sidhu, Js
Bansal, Ajesh
Goyal, Omesh
Sidhu, Gursewak
Nanda, Vijay
Saluja, Harmeet
Sehgal, Alok
Simran, Sidhu
Kishore, Harsh
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S383 - S383
[28] Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy
Bolkhir, Ahmed
Brunt, Elizabeth M.
Solomon, Harvey S.
Hayashi, Paul H.
LIVER TRANSPLANTATION, 2007, 13 (02) : 309 - 311
[29] Fibrosing cholestatic hepatitis after liver transplantation for hepatitis C virus
不详
VIRCHOWS ARCHIV, 2005, 447 (02) : 144 - 144
[30] Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation
Dinges, S.
Morard, I.
Heim, M.
Dufour, J.-F.
Mullhaupt, B.
Giostra, E.
Clavien, P. -A.
Mentha, G.
Negro, F.
TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 33 - 39

← 1 2 3 4 5 →